Selecione o seu país ou região

Agora você está em Norway (Norsk)
Página inicial / Sobre nós / Investors / Newsroom / Arjo’s interim report January-June 2023
❮ Notícias

Arjo’s interim report January-June 2023

”The recovery following a turbulent 2022 continues and we grew 5% organically with improved profitability and strong cash flow. Demand was healthy in many markets and despite continuing challenging market conditions in the US, we expect to deliver organic growth for the full-year within our target interval of 3–5%,” says Joacim Lindoff, President and CEO of Arjo.

 April-June 2023 in brief

  • Net sales increased to SEK 2,686 M (2,404).
    Net sales grew organically by 5.0%.
  • Adjusted EBITDA rose to SEK 490 M (430).
  • Adjusted operating profit increased to SEK 206 M (165).
  • Profit after financial items amounted to SEK 135 M (139).
  • Earnings per share amounted to SEK 0.37 (0.38).
  • Cash flow from operations increased to SEK 528 M (158).
  • Cash conversion increased to 112.5% (37.4).
     

Telephone conference

Fund managers, analysts and media are invited to participate in a conference call and presentation of the report on July 14 at 08.00 CEST via the following link:https://ir.financialhearings.com/arjo-q2-2023

Those who wish to ask questions verbally via the teleconference will need to register via the link below. A phone number and a conference ID will be provided after registration in order to access the conference. Link to registration:
https://conference.financialhearings.com/teleconference/?id=200819

Alternatively, use the following link to download the presentation:
https://www.arjo.com/int/about-us/investors/reports--presentations/2023/

A recorded version of the conference is accessible for three years via the following link:
https://ir.financialhearings.com/arjo-q2-2023

 
For more information, please contact:

Maria Nilsson, EVP Communications & Public Relations

Tel: +46 734 244 515

Email: maria.nilsson@arjo.com  

 

Sara Ehinger, VP Investor Relations & Corporate Communications

Tel: +46 723 597 794

Email: sara.ehinger@arjo.com


This information is information that Arjo AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 07:00 CEST on July 14, 2023.


About Arjo

At Arjo, we believe that empowering movement within healthcare environments is essential to quality care. Our products and solutions are designed to promote a safe and dignified experience through patient handling, medical beds, personal hygiene, disinfection, diagnostics, and the prevention of pressure injuries and venous thromboembolism. With 6,800 people worldwide and 65 years caring for patients and healthcare professionals, we are committed to driving healthier outcomes for people facing mobility challenges. www.arjo.com

Arjo_Q2_2023_ENG_FINAL